Baseline demographics
| Values*, n=60 | |
| Demographics | |
| Female sex, (%) | 32 (53.3) |
| Age (years) | 58.5 (52, 68) |
| BMI (kg/m2) | 26.6 (22.6, 32.6) |
| Race, (%) | White: 54 (90) Black: 2 (3.3) Asian: 2 (3.3) White/Asian: 1 (1.7) White/Pacific Islander: 1 (1.7) |
| Ethnicity, (%) | Non-Hispanic: 60 (100) |
| Personal history of autoimmune disease, (%) | Psoriasis: 1 (1.7) Hypothyroidism: 1 (1.7) |
| Family history of autoimmune disease, (%) | Crohn’s disease: 2 (3.3) Rheumatoid arthritis: 2 (3.3) Ankylosing spondylitis and Crohn’s disease: 1 (1.7) Juvenile idiopathic arthritis: 1 (1.7) Polymyalgia rheumatica: 1 (1.7) |
| Total ICI duration (months) | 7 (2, 13) |
| Follow-up from ICI cessation (months) | 9 (5, 20.5) |
| Tumour type, (%)† | Melanoma: 21 (35) NSCLC: 14 (23.3) Other: 11 (18.3) Gastrointestinal: 7 (11.7) Genitourinary: 4 (6.7) Gynaecologic: 3 (5) |
| Immunotherapy, (%) | Combination: 18/60 (30) Monotherapy: 42/60 (70) |
| Baseline tumour response, (%) | CR: 14 (23.3) PR: 10 (16.7) NED: 4 (6.7) SD: 17 (28.3) PD: 15 (25.0) |
*Values expressed as number (percentage) or median (IQR) as appropriate.
†Gastrointestinal cancers included pancreatic adenocarcinoma, colon adenocarcinoma, hepatocellular carcinoma and duodenal adenocarcinoma. Genitourinary cancers included renal cell carcinoma, prostate adenocarcinoma and urothelial carcinoma. Gynaecological cancers included cervical squamous cell carcinoma, clear cell endometrial carcinoma, and endometrial carcinosarcoma. Other cancers included Hodgkin’s lymphoma, Kaposi sarcoma, mesothelioma, mycosis fungoides, neuroendocrine carcinoma, ependymoma, ductal carcinoma of the breast, basal cell carcinoma and cutaneous squamous cell carcinoma.
BMI, body mass index; CR, complete response; ICI, immune checkpoint inhibitor; NED, no evidence of disease; NSCLC, non-small cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease.